Novel sulfonyl thiazolyl-hydrazone derivatives as EGFR inhibitors: Design, synthesis, biological evaluation and molecular docking studies
作者:Thoraya A. Farghaly、Eman M.H. Abbas、Amerah M. Al-Soliemy、Rehab Sabour、Mohamed R. Shaaban
DOI:10.1016/j.bioorg.2022.105684
日期:2022.4
New hydrazonoyl-sulfonylthiazoles were designed and synthesized as EGFR inhibitors. The new sulfonylthiazole derivatives were assessed in vitro to measure their effect on EGFR. They revealed marked inhibitory activity against EGFR kinase having IC50 range from 0.037 to 0.317 μM compared to reference drug dasatinib (IC50 = 0.077 μM). Six derivatives of the newly synthesized compounds showed potent inhibitory
设计并合成了新的腙酰基-磺酰基噻唑作为EGFR抑制剂。在体外评估了新的磺酰噻唑衍生物以测量它们对 EGFR 的影响。与参考药物达沙替尼(IC 50 = 0.077 μM)相比,他们揭示了对 EGFR 激酶的显着抑制活性,IC 50范围为 0.037 至 0.317 μM。新合成化合物的六种衍生物相对于达沙替尼显示出有效的抑制活性。此外,使用MTT测定法检查了新命中物对人乳腺癌细胞系(MCF7)、肝癌细胞系(HepG2)的细胞毒性作用。N -(2-Benzenesulfonyl-1-phenyl-ethyleneidene) -N' -(4-methyl-thiazol-2-yl)-肼 (IC 50 = 1.24 μM) 显示对 MCF7 细胞系的效力高于达沙替尼 (IC 50 = 11.6 μM)。此外,N -(2-benzosulfonyl-1-phenyl-ethyleneidene)